Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Champions Oncology Inc
2I3Current price
4.22 EUR
-0.06 EUR (-1.40%)
Last closed
4.64 USD
Company
www.championsoncology.com
ISIN
US15870P3073
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
61 308 040 USD
Yield for 12 month
-15.05 %
1Y
3Y
5Y
10Y
15Y
2I3
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey. Address: One University Plaza, Hackensack, NJ, United States, 07601
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
6 USDP/E ratio
–Dividend Yield
–Current Year
+50 155 000 USD
Last Year
+53 870 000 USD
Current Quarter
+14 061 000 USD
Last Quarter
+14 001 000 USD
Current Year
+20 754 000 USD
Last Year
+24 338 000 USD
Current Quarter
+6 989 000 USD
Last Quarter
+6 751 000 USD
Key Figures 2I3
1 year
3 years
5 years
10 years
EBITDA
-1 169 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-6.93 %
PEG Ratio
–
Return On Equity TTM
-432.46 %
Wall Street Target Price
6 USD
Revenue TTM
51 655 000 USD
Book Value
-0.024 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
11.9 %
Dividend Yield
–
Gross Profit TTM
24 338 000 USD
Earnings per share
-0.26 USD
Diluted Eps TTM
-0.26 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
-28.6 %
Profit Margin
-6.58 %
Dividend Analytics 2I3
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 2I3
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:12
Payout Ratio
–
Last Split Date
12.08.2015
Dividend Date
–
Stock Valuation 2I3
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
22.8833
Enterprise Value Revenue
1.2593
Price Sales TTM
1.1777
Enterprise Value EBITDA
26.2588
Price Book MRQ
6.7705
Financials 2I3
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 2I3
For 52 weeks
3.6 USD
7.13 USD
50 Day MA
4.42 USD
Shares Short Prior Month
217 703
200 Day MA
4.91 USD
Short Ratio
7.53
Shares Short
200 104
Short Percent
3.64 %
BeatStart